Another Early Win for TAVI in Low-Risk Patients
Transcatheter aortic-valve implantation (TAVI) has become the dominant, if not default, therapy for patients with severe, symptomatic aortic stenosis who are at intermediate, high, or prohibitive risk for surgical aortic-valve replacement (SAVR). Several randomized trials have shown that TAVI in pat...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2024-05, Vol.390 (17), p.1623-1625 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1625 |
|---|---|
| container_issue | 17 |
| container_start_page | 1623 |
| container_title | The New England journal of medicine |
| container_volume | 390 |
| creator | Shah, Pinak B. |
| description | Transcatheter aortic-valve implantation (TAVI) has become the dominant, if not default, therapy for patients with severe, symptomatic aortic stenosis who are at intermediate, high, or prohibitive risk for surgical aortic-valve replacement (SAVR). Several randomized trials have shown that TAVI in patients at low surgical risk is either noninferior or superior in safety and efficacy as compared with SAVR at 1 to 2 years.
1-3
Moreover, longer-term clinical outcomes of TAVI as compared with SAVR in such patients have held up at 4 years in the Evolut Low Risk trial,
4
5 years in the PARTNER 3 trial,
5
and 10 years in the . . . |
| doi_str_mv | 10.1056/NEJMe2402934 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3035074211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3049787427</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-e54eedd52311c337f8caddeb67f1d54a7d893491959946b66b1337747dd2adbe3</originalsourceid><addsrcrecordid>eNpt0M9LwzAUB_AgipvTm2cp6MGDdUmTNMlxjKmT-QOZeixp84qd_bElLbL_3simiPgu7x0-fHl8ETom-JJgHg_vJ7d3EDEcKcp2UJ9wSkPGcLyL-hhHMmRC0R46cG6B_RCm9lGPSi4lxrKPhqO6ad_ABhNty3XwWtRB3thgPnqZBv6eNR_hU-Heg0fdFlC37hDt5bp0cLTdA_R8NZmPb8LZw_V0PJqFGcW8DYEzAGN4RAnJKBW5zLQxkMYiJ4YzLYz07yqiuFIsTuM4JV4JJoyJtEmBDtD5Jndpm1UHrk2qwmVQlrqGpnMJxZRjwSJCPD39QxdNZ2v_nVdMCemZ8OpiozLbOGchT5a2qLRdJwQnX0Umv4v0_GQb2qUVmB_83ZwHZxtQVS6pYVH9n_MJa_51Lw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3049787427</pqid></control><display><type>article</type><title>Another Early Win for TAVI in Low-Risk Patients</title><source>MEDLINE</source><source>New England Journal of Medicine Current</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><creator>Shah, Pinak B.</creator><creatorcontrib>Shah, Pinak B.</creatorcontrib><description>Transcatheter aortic-valve implantation (TAVI) has become the dominant, if not default, therapy for patients with severe, symptomatic aortic stenosis who are at intermediate, high, or prohibitive risk for surgical aortic-valve replacement (SAVR). Several randomized trials have shown that TAVI in patients at low surgical risk is either noninferior or superior in safety and efficacy as compared with SAVR at 1 to 2 years.
1-3
Moreover, longer-term clinical outcomes of TAVI as compared with SAVR in such patients have held up at 4 years in the Evolut Low Risk trial,
4
5 years in the PARTNER 3 trial,
5
and 10 years in the . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMe2402934</identifier><identifier>PMID: 38588008</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Aortic stenosis ; Aortic Valve - surgery ; Aortic Valve Stenosis - surgery ; Cardiology ; Cardiology General ; Cardiovascular Surgery ; Clinical trials ; Heart ; Humans ; Patients ; Risk ; Risk groups ; Surgery ; Transcatheter Aortic Valve Replacement - adverse effects ; Valvular Heart Disease</subject><ispartof>The New England journal of medicine, 2024-05, Vol.390 (17), p.1623-1625</ispartof><rights>Copyright © 2024 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c305t-e54eedd52311c337f8caddeb67f1d54a7d893491959946b66b1337747dd2adbe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMe2402934$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3049787427?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38588008$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shah, Pinak B.</creatorcontrib><title>Another Early Win for TAVI in Low-Risk Patients</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Transcatheter aortic-valve implantation (TAVI) has become the dominant, if not default, therapy for patients with severe, symptomatic aortic stenosis who are at intermediate, high, or prohibitive risk for surgical aortic-valve replacement (SAVR). Several randomized trials have shown that TAVI in patients at low surgical risk is either noninferior or superior in safety and efficacy as compared with SAVR at 1 to 2 years.
1-3
Moreover, longer-term clinical outcomes of TAVI as compared with SAVR in such patients have held up at 4 years in the Evolut Low Risk trial,
4
5 years in the PARTNER 3 trial,
5
and 10 years in the . . .</description><subject>Aortic stenosis</subject><subject>Aortic Valve - surgery</subject><subject>Aortic Valve Stenosis - surgery</subject><subject>Cardiology</subject><subject>Cardiology General</subject><subject>Cardiovascular Surgery</subject><subject>Clinical trials</subject><subject>Heart</subject><subject>Humans</subject><subject>Patients</subject><subject>Risk</subject><subject>Risk groups</subject><subject>Surgery</subject><subject>Transcatheter Aortic Valve Replacement - adverse effects</subject><subject>Valvular Heart Disease</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0M9LwzAUB_AgipvTm2cp6MGDdUmTNMlxjKmT-QOZeixp84qd_bElLbL_3simiPgu7x0-fHl8ETom-JJgHg_vJ7d3EDEcKcp2UJ9wSkPGcLyL-hhHMmRC0R46cG6B_RCm9lGPSi4lxrKPhqO6ad_ABhNty3XwWtRB3thgPnqZBv6eNR_hU-Heg0fdFlC37hDt5bp0cLTdA_R8NZmPb8LZw_V0PJqFGcW8DYEzAGN4RAnJKBW5zLQxkMYiJ4YzLYz07yqiuFIsTuM4JV4JJoyJtEmBDtD5Jndpm1UHrk2qwmVQlrqGpnMJxZRjwSJCPD39QxdNZ2v_nVdMCemZ8OpiozLbOGchT5a2qLRdJwQnX0Umv4v0_GQb2qUVmB_83ZwHZxtQVS6pYVH9n_MJa_51Lw</recordid><startdate>20240502</startdate><enddate>20240502</enddate><creator>Shah, Pinak B.</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20240502</creationdate><title>Another Early Win for TAVI in Low-Risk Patients</title><author>Shah, Pinak B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-e54eedd52311c337f8caddeb67f1d54a7d893491959946b66b1337747dd2adbe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aortic stenosis</topic><topic>Aortic Valve - surgery</topic><topic>Aortic Valve Stenosis - surgery</topic><topic>Cardiology</topic><topic>Cardiology General</topic><topic>Cardiovascular Surgery</topic><topic>Clinical trials</topic><topic>Heart</topic><topic>Humans</topic><topic>Patients</topic><topic>Risk</topic><topic>Risk groups</topic><topic>Surgery</topic><topic>Transcatheter Aortic Valve Replacement - adverse effects</topic><topic>Valvular Heart Disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shah, Pinak B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shah, Pinak B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Another Early Win for TAVI in Low-Risk Patients</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2024-05-02</date><risdate>2024</risdate><volume>390</volume><issue>17</issue><spage>1623</spage><epage>1625</epage><pages>1623-1625</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Transcatheter aortic-valve implantation (TAVI) has become the dominant, if not default, therapy for patients with severe, symptomatic aortic stenosis who are at intermediate, high, or prohibitive risk for surgical aortic-valve replacement (SAVR). Several randomized trials have shown that TAVI in patients at low surgical risk is either noninferior or superior in safety and efficacy as compared with SAVR at 1 to 2 years.
1-3
Moreover, longer-term clinical outcomes of TAVI as compared with SAVR in such patients have held up at 4 years in the Evolut Low Risk trial,
4
5 years in the PARTNER 3 trial,
5
and 10 years in the . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>38588008</pmid><doi>10.1056/NEJMe2402934</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2024-05, Vol.390 (17), p.1623-1625 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3035074211 |
| source | MEDLINE; New England Journal of Medicine Current; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland |
| subjects | Aortic stenosis Aortic Valve - surgery Aortic Valve Stenosis - surgery Cardiology Cardiology General Cardiovascular Surgery Clinical trials Heart Humans Patients Risk Risk groups Surgery Transcatheter Aortic Valve Replacement - adverse effects Valvular Heart Disease |
| title | Another Early Win for TAVI in Low-Risk Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T13%3A59%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Another%20Early%20Win%20for%20TAVI%20in%20Low-Risk%20Patients&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Shah,%20Pinak%20B.&rft.date=2024-05-02&rft.volume=390&rft.issue=17&rft.spage=1623&rft.epage=1625&rft.pages=1623-1625&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMe2402934&rft_dat=%3Cproquest_cross%3E3049787427%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3049787427&rft_id=info:pmid/38588008&rfr_iscdi=true |